InMed Pharmaceuticals Inc. (INM)

0.2600 +0.0039 (+1.52%) As of 03:32PM EDT. Market open.

InMed Pharmaceuticals Inc.

815 West Hastings Street
Suite 310
Vancouver, BC V6C 1B4
Canada
604 669 7207
https://www.inmedpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 13

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Eric A. Adams B.S. Chem., M.I.B.	President, CEO & Director	347.82k	N/A	1963
Mr. Michael Woudenberg P.Eng.	Chief Operating Officer	287.54k	N/A	1969
Ms. Alexandra Diane-Janet Mancini M.Sc.	Senior Vice President of Clinical & Regulatory Affairs	279.39k	N/A	1953
Dr. Sazzad Hossain M.Sc., Ph.D.	Co-Founder	134.05k	N/A	1958
Ms. N. Netta Jagpal	CFO & Corporate Secretary	N/A	N/A	1973
Ms. Sarah Li CPA, CGA	VP of Accounting & Controller	N/A	N/A	N/A
Colin Clancy	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Jerry P. Griffin	Vice President of Sales & Marketing	N/A	N/A	N/A
Dr. Eric Chih-Hsien Hsu	Senior Vice President of Preclinical Research & Development	253.46k	N/A	1970
Dr. Shane A. Johnson Ph.D.	Senior VP & GM of BayMedica	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Corporate Governance

InMed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.